AzTrials
AzTrials

Acute Myeloid LeukemiaPhase 1NCT05823480

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

A Phase 1 study testing Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine and Biospecimen Collection in people with Acute Myeloid Leukemia and Myelodysplastic Syndrome, run by City of Hope Medical Center.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This phase I trial studies how well the combination of magrolimab works with azacitidine after a donor stem cell transplant (allogeneic hematopoietic cell transplantation) in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Magrolimab is a type of protein called an antibody. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine and Biospecimen Collection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
9 Oct 2024to 14 Feb 2026
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Documented informed consent of the patient and/or legally authorized representative (done within 30 days of HCT day 0).
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies.
  • If unavailable, exceptions may be granted with study principal investigator (PI) approval.
  • Age: 18-75 years old.
  • Eastern Cooperative Oncology Group =< 2.
  • Patients who are scheduled to undergo allogeneic HCT for AML with high-risk cytogenetics per European Leukemia Net (ELN) or MDS with International Prognostic Scoring System (IPSS) of intermediate 2 with poor risk cytogenetics or molecular markers. OR patients with MRD+ disease OR active disease with < 10% blast at the time of HCT.
Show all 23Show fewer
  • Patients who are scheduled to undergo their first or second HCT with reduced intensity conditioning regimen (any reduced intensity conditioning regimen per institutional standards is allowed), and regardless of GVHD prophylactic regimen.
  • Allogeneic transplant regardless of donor type (matched, mismatched, haploidentical, etc.) or graft source (bone marrow or mobilized peripheral blood stem cells) are included.
  • Pre-HCT exposure to anti-CD47 of hypomethylating agent (HMA) is allowed if no progression on therapy has been documented.
  • Absolute neutrophil count (ANC) >= 1.5 (without the use of granulocyte-colony stimulating factor [GCSF] for last 2 weeks) (To be performed within 45 days prior to transplant unless otherwise stated).
  • NOTE: Transfusion (Red blood cells [RBC] or platelet) to achieve the above-mentioned counts is allowed.
  • Platelet count >= 50K (To be performed within 45 days prior to transplant unless otherwise stated).
  • NOTE: Transfusion (RBC or platelet) to achieve the above-mentioned counts is allowed.
  • NOTE: Complete blood count (CBC) should be done within 2 weeks of day 1 of the protocol.
  • Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (To be performed within 45 days prior to transplant unless otherwise stated).
  • Aspartate transaminase (AST) =< 1.5X ULN (To be performed within 45 days prior to transplant unless otherwise stated).
  • Alanine transaminase (ALT) =< 1.5 X ULN (To be performed within 45 days prior to transplant unless otherwise stated).
  • Creatinine clearance of >= 60 mL/min per 24-hour urine test or the Cockcroft-Gault formula (To be performed within 45 days prior to transplant unless otherwise stated).
  • Left ventricular ejection fraction (LVEF) >= 45% (To be performed within 45 days prior to transplant unless otherwise stated).
  • If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) (diffusion capacity) >= 50% of predicted (corrected for hemoglobin). If unable to perform pulmonary function tests: oxygen (O2) saturation > 92% on room air. (To be performed within 45 days prior to transplant unless otherwise stated).
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. (To be performed within 45 days prior to transplant unless otherwise stated).
  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.
  • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

Who cannot join

  • Patient who underwent more than 2 allogeneic HCTs.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents (azacitidine or magrolimab).
  • Females only: Pregnant or breastfeeding.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • Known inherited or acquired bleeding disorders.
  • Clinical suspicion of active central nervous system (CNS) involvement by MDS.
Show all 9Show fewer
  • Significant medical diseases or conditions, including but not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes, significant active infection and congestive heart failure (CHF) New York Heart Association (NYHA) class 3-4.
  • Known or active hepatitis B or C infection or human immunodeficiency virus (HIV) infection in medical history.
  • Prospective patients who, in the opinion of the principal investigator (PI), may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

About this study

Official title: A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) with Azacitidine As Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS

This phase I trial studies how well the combination of magrolimab works with azacitidine after a donor stem cell transplant (allogeneic hematopoietic cell transplantation) in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Magrolimab is a type of protein called an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to protect themselves from the body's immune system. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. Azacitidine is a chemotherapy drug that may prevent the return of acute myeloid leukemia or myelodysplastic syndrome by working in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining magrolimab and azacitidine may kill more cancer cells after allogeneic hematopoietic cell transplantation in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.

Read the detailed description

PRIMARY OBJECTIVE:

  1. Establish safety/feasibility and determine the recommended phase 2 dose (RP2D) of magrolimab in combination with a fixed dose of azacitidine when given as the maintenance therapy after reduced intensity conditioning allogeneic hematopoietic cell transplantation (HCT), in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

SECONDARY OBJECTIVES:

  1. Estimate overall survival (OS), progression-free survival (PFS), cumulative incidence (CI) of relapse/progression, non-relapse mortality (NRM) at +100 days and 1-year post- maintenance therapy.

II. Estimate CI of acute graft-versus-host disease (GVHD) at 180 days post HCT, and chronic GVHD at one-year post-HCT.

III. Longitudinally characterize minimal residual disease (MRD+) status in patients receiving maintenance therapy.

IV. Feasibility of receiving magrolimab in combination with azacitidine as maintenance therapy in this patient population.

EXPLORATORY OBJECTIVES:

  1. Characterize the presence and level of GVHD biomarkers and inflammatory cytokines in the first 100 days from the start of maintenance therapy.

II. Assess the possible correlation between chimerism kinetics by AlloHeme assay (per next generation sequencing [NGS] assay) and post-HCT relapse.

III. Describe kinetics of immune cell recovery and macrophage activation in the first-year post-HCT.

IV. Assess health related quality of life (QoL) and symptoms on days 1, 60, 90 and 180 after starting maintenance therapy.

OUTLINE: This is a dose-escalation study of magrolimab (MRD- patients only), followed by a dose-expansion study (MRD- and MRD+ patients).

Patients undergo allo HCT per standard of care. Patients then receive magrolimab intravenously (IV) and azacitidine IV on study. Patients undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) during screening and blood sample collection and bone marrow biopsy and aspirate throughout the study.

Being tested
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
Medical subject headings
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure or surgery

    Also called Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC

    Undergo allo HCT per standard of care

  • AzacitidineDrug

    Also called 5 AZC, 5-AC, 5-Azacytidine, 5-AZC

    Given IV

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood sample collection

  • Bone Marrow AspirateProcedure or surgery

    Also called Human Bone Marrow Aspirate

    Undergo bone marrow biopsy and aspirate

  • Bone Marrow BiopsyProcedure or surgery

    Also called Biopsy of Bone Marrow, Biopsy, Bone Marrow

    Undergo bone marrow biopsy and aspirate

  • EchocardiographyProcedure or surgery

    Also called EC

    Undergo ECHO

  • MagrolimabBiological

    Also called Hu5F9-G4

    Given IV

  • Multigated Acquisition ScanProcedure or surgery

    Also called Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA

    Undergo MUGA

  • Questionnaire AdministrationOther

    Ancillary studies

Study groups in NCT05823480
Study groupRoleWhat they receive
Treatment (magrolimab, azacitidine)ExperimentalPatients undergo allo HCT per standard of care. Patients then receive magrolimab IV and azacitidine IV on study. Patients undergo ECHO or MUGA during screening and blood sample collection and bone marrow biopsy and aspirate throughout the study.
Receives: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Azacitidine; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspirate; Procedure: Bone Marrow Biopsy; Procedure: Echocardiography; Biological: Magrolimab; Procedure: Multigated Acquisition Scan; Other: Questionnaire Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of dose-limiting toxicities

    Dose limiting toxicities (DLT) are defined as any of the following events that are attributed at least possibly due to study regimen and occur from start of magrolimab (day +1) to the end of the first cycle of magrolimab maintenance (day +85 +/-7): Death, grade 3-4 non-hematological toxicities per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0), grade 4 hematological toxicities per NCI CTCAE 5.0 that last for more than 21 days. Will utilize the revised National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 for adverse events reporting.

    Measured: The evaluation period of DLT is from starting study regimen (day + 1) to the first observation of DLT, or the end of the first cycle of Magrolimab maintenance (day +85) with a grace period of ±7days, whichever comes first. (Each cycle is 28 days)

  2. Maximum tolerated dose (MTD) and recommended phase 2 dose (RPD) of magrolimab

    Will use the time-to-event Bayesian optimal interval (TITE-BOIN) design [1] to find the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D).

    Measured: The evaluation period of DLT is from starting study regimen (day + 1) to the first observation of DLT, or the end of the first cycle of Magrolimab maintenance (day +85) with a grace period of ±7days, whichever comes first. (Each cycle is 28 days)

Secondary outcomes (8)

  1. Overall survival

    Measured: Time period from start of protocol therapy to death regardless of cause, assessed up to 6 years

  2. Progression free survival

    Measured: Time from start of protocol therapy to relapse/progression, or death, whichever comes first, assessed up to 6 years

  3. Cumulative incidence of relapse/progression (CIR)

    Will be estimated using the cumulative incidence.

    Measured: Time of start of treatment to time of relapse/progression, assessed up to 6 years

  4. Cumulative incidence of on-relapse mortality (NRM)

    Will be estimated using the cumulative incidence.

    Measured: Time of start of treatment to non-disease related death, assessed up to 6 years

  5. Cumulative incidence of acute graft versus host disease (aGvHD) of grades 2-4 and 3-4

    Will be assessed by documented or biopsy proven aGvHD and graded according to the Mount Sinai Acute GVHD International Consortium (MAGIC) grading. Will be estimated using the cumulative incidence curve.

    Measured: Time of start of treatment to first documented/biopsy proven acute GVHD onset date, at 180 days post transplant

  6. Cumulative incidence of chronic graft versus host disease (cGvHD)

    Will be assessed by documented or biopsy proven cGvHD and scored according to the National Institutes of Health (NIH) Consensus Staging. Disease relapse/progression or NRM is considered competing risk events. cGvHD will be censored at time of last follow-up if patients remain alive and free of relapse/progression. cGvHD will be estimated using the cumulative incidence curve.

    Measured: Time of start of treatment to first documented/biopsy proven chronic GVHD onset date, assessed at 1 year post transplant

  7. Minimal residual disease

    Will be assessed from bone marrow aspirates collected on days 30, 100, and 180 post HCT.

    Measured: Assessed up to 6 years

  8. Completion of planned therapy

    Feasibility is defined as ability to complete at least 30% of the planned therapy.

    Measured: Assessed up to 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2023
  2. Study start9 Oct 2024 (estimated)
  3. Primary completion14 Feb 2026 (estimated)
  4. Study completion14 Feb 2026 (estimated)

Why it stopped: Withdrawn -ctms

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05823480
Sponsor's protocol ID
22618
Other IDs
NCI-2023-02417, 22618, P30CA033572
Status last verified
Sep 2024
First submitted
29 Mar 2023
Last updated
19 Sep 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine and Biospecimen Collection in people with Acute Myeloid Leukemia and Myelodysplastic Syndrome, run by City of Hope Medical Center.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 19 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of dose-limiting toxicities (time frame: The evaluation period of DLT is from starting study regimen (day + 1) to the first observation of DLT, or the end of the first cycle of Magrolimab maintenance (day +85) with a grace period of ±7days, whichever comes first. (Each cycle is 28 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05823480.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in